Author(s):
B. Bhuvaneswari, Ramya Ravichandar, K. Punnagai, P. Pravallika, G. Avinash Kumar
Email(s):
dravinashreddy88@gmail.com
DOI:
10.52711/0974-360X.2026.00643 
Address:
B. Bhuvaneswari1, Ramya Ravichandar1, K. Punnagai1, P. Pravallika2, G. Avinash Kumar3*
1Department of Pharmacology, Tagore Medical College and Hospital, Rathinamangalam, Chennai - 600127, Tamil Nadu, India.
2Department of Pharmacology, Vel Pharmacy College, VISTAS, Manjankaranai, Thiruvallur - 601102, Tamil Nadu, India.
3Department of Pharmacognosy, Vel Pharmacy College, VISTAS, Manjankaranai, Thiruvallur - 601102, Tamil Nadu, India.
*Corresponding Author
Published In:
Volume - 19,
Issue - 10,
Year - 2026
ABSTRACT:
Multidrug resistance (MDR) remains a significant barrier to effective cancer treatment, particularly in chemotherapy. ATP-binding cassette (ABC) transporter is a key player in this resistance, actively effluxing chemotherapeutic drugs out of cells. This study investigated the potential of natural compounds, cinnamaldehyde and cinnamic acid, to reverse MDR and enhance the efficacy of oxaliplatin in colon cancer cells. The MTT assay of cinnamaldehyde and cinnamic acid in combination with oxaliplatin on Caco-2 cell lines, showed reduced IC50 value of oxaliplatin similar to standard drug, verapamil. Molecular docking studies were performed to analyze interactions with ABC proteins ABCB1 (7A6E), ABCB6 (3NH6), ABCC1 (5UJA), ABCG2 (6VXI) and BRAF (2FB8). ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) analysis revealed superior bioavailability and lower toxicity of cinnamic acid compared to cinnamaldehyde showing better drug-likeness of the compound. Molecular docking showed that cinnamic acid exhibited strong binding affinity with P-gp, ABCG2, ABCB6 and BRAF. ADMET analysis. Molecular dynamics simulations involving RMSD, RMSF showed stability and flexibility of interactions between cinnamic acid and ABCG2, BRAF. MMGBSA data revealed the structural integrity of the bonds. DCC and PCA studies demonstrated stable interactions between cinnamic acid and 2 receptors. Cinnamic acid shows promise as a potential inhibitor of drug efflux via ABCG2 and MAPK signaling via BRAF alongside P-gp inhibition that could enhance the efficacy of oxaliplatin in the treatment of colon cancer, addressing MDR. Further in vivo studies and development of drug delivery systems could translate these findings into clinical applications, improving cancer treatment outcomes.
Cite this article:
B. Bhuvaneswari, Ramya Ravichandar, K. Punnagai, P. Pravallika, G. Avinash Kumar. Reversing Multidrug Resistance with Cinnamaldehyde and Cinnamic acid - An invitro and insilico study on Oxaliplatin Resistant Colon Cancer. Research Journal Pharmacy and Technology. 2026;19(10):4621-9. doi: 10.52711/0974-360X.2026.00643
Cite(Electronic):
B. Bhuvaneswari, Ramya Ravichandar, K. Punnagai, P. Pravallika, G. Avinash Kumar. Reversing Multidrug Resistance with Cinnamaldehyde and Cinnamic acid - An invitro and insilico study on Oxaliplatin Resistant Colon Cancer. Research Journal Pharmacy and Technology. 2026;19(10):4621-9. doi: 10.52711/0974-360X.2026.00643 Available on: https://rjptonline.org/AbstractView.aspx?PID=2026-19-10-19
8. REFERENCES:
1. Vidya BM, Sireesha V, Venkateswara RM. Survival Analysis of Colon Cancer Data using Quantile Regression. Research Journal of Pharmacy and Technology. 2023; 16(3): 1401-8.
2. Duan C, Yu M, Xu J, Li BY, Zhao Y, Kankala RK. Overcoming Cancer Multi-drug Resistance (MDR): Reasons, mechanisms, nanotherapeutic solutions, and challenges. Biomedicine and Pharmacotherapy. 2023;162:114643.
3. Goebel J, Chmielewski J, Hrycyna CA. The roles of the human ATP-binding cassette transporters P-glycoprotein and ABCG2 in multidrug resistance in cancer and at endogenous sites: Future opportunities for structure-based drug design of inhibitors. Cancer Drug Resistance. 2021; 4(4): 784.
4. Dhavale SS, Bhosle AV, Hardikar SR, Kotkar TR. Significance of P-Glycoproteins as a Transporter System. Research Journal of Pharmacy and Technology. 2008; 1(4): 298-309.
5. Mollazadeh S, Sahebkar A, Hadizadeh F, Behravan J, Arabzadeh S. Structural and functional aspects of P-glycoprotein and its inhibitors. Life Sciences. 2018; 214: 118-123.
6. Paterson JK, Szakacs G, Tachiwada T, Akiyama SI, Gottesman MM. The role of ABCB6 in multidrug resistance. Cancer Research. 2005; 65(9_Supplement): 122.
7. Park S, Shimizu C, Shimoyama T, Takeda M, Ando M, Kohno T, Katsumata N, et al. Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Research and Treatment. 2006; 99: 9-17.
8. Dvorak P, Hlavac V, Mohelnikova-Duchonova B, Liska V, Pesta M, Soucek P. Downregulation of ABC transporters in non-neoplastic tissues confers better prognosis for pancreatic and colorectal cancer patients. Journal of Cancer. 2017; 8: 1959–71.
9. Cole SPC. Multidrug resistance protein 1 (MRP1, ABCC1), a “multitasking” ATP-binding cassette (ABC) transporter. Journal of Biological Chemistry. 2014; 289: 30880–88.
10. Muriithi W, Macharia LW, Heming CP, Echevarria JL, Nyachieo A, Filho PN, Neto VM. ABC transporters and the hallmarks of cancer: roles in cancer aggressiveness beyond multidrug resistance. Cancer Biology and Medicine. 2020; 17(2): 253-269.
11. Korphaisarn K, Kopetz S. BRAF-Directed Therapy in Metastatic Colorectal Cancer. Cancer Journal. 2016; 22(3): 175-8.
12. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012; 483: 100–103.
13. Ardianto C, Judoko AL, Aprilia M, Ratri DMN, Ariyani T, Rahmadi M, Khotib J. Effect of andrographolide and resveratrol on OX1R and prepro-orexin mRNA expression in CIPN-induced hypothalamus of mice with oxaliplatin. Research Journal of Pharmacy and Technology. 2022; 15(10): 4765-4771.
14. Martinez-Balibrea E, Martínez-Cardús A, Ginés A, Ruiz de Porras V, Moutinho C, Layos L, Manzano JL, Bugés C, Bystrup S, Esteller M, Abad A. Tumor-related molecular mechanisms of oxaliplatin resistance. Molecular Cancer Therapeutics. 2015; 14(8): 1767-1776.
15. Tian Y, Lei Y, Wang Y, Lai J, Wang J, Xia F. Mechanism of multidrug resistance to chemotherapy mediated by P-glycoprotein. International Journal of Oncology. 2023; 63(5): 119.
16. Wang Q, Shen X, Chen G, Du J. Drug Resistance in Colorectal Cancer: From Mechanism to Clinic. Cancers. 2022; 14(12): 2928.
17. Kumar A, Jaitak V. Natural products as multidrug resistance modulators in cancer. European Journal of Medicinal Chemistry. 2019; 176: 268-291.
18. Guo J, Jiang X, Tian Y, Yan S, Liu J, Xie J, Zhang F, Yao C, Hao E. Therapeutic Potential of Cinnamon Oil: Chemical Composition, Pharmacological Actions, and Applications. Pharmaceuticals. 2024; 17(12): 1700.
19. Chetashri NP, Swati UK, Manthan RR, Swapnil SL, Asawari PM. Cinnamon an all-Inclusive Review: Detailed Examination of the Botanical Characteristics, Pharmacological properties, and Therapeutic Potential of Diverse Cinnamon Species. Asian Journal of Research in Pharmaceutical Sciences. 2024; 14(3): 249-5.
20. Sadika B, Ramakrishnaiah TN. Screening of Garcinia cambogia for in-Vitro Anti-Cancerous Activity against Colon Adenocarcinoma (Caco-2) Cell Line. Research Journal of Pharmacognosy and Phytochemistry. 2018; 10(4): 272-276.
21. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Scientific Reports. 2017; 7(1): 1–13.
22. Tian C, Kasavajhala K, Belfon KA, Raguette L, Huang H, Migues AN, Bickel J, Wang Y, Pincay J, Wu Q, Simmerling C. ff19SB: Amino-acid-specific protein backbone parameters trained against quantum mechanics energy surfaces in solution. Journal of Chemical Theory and Computation. 2019; 16(1): 528-552.
23. Case HM, Aktulga K, Belfon DS, Cerutti GA, Cisneros VW, Cruzeiro N, Forouzesh T, Giese TJ, Götz AW, Gohlke H, Goetz A, et al. AmberTools. Journal of Chemical Information and Modeling. 2023; 63(20): 6183-6191.
24. Eastman J, Swails J.D, Chodera RT, McGibbon Y, Zhao K.A, Beauchamp L.-P, Wang A.C, Simmonett MP, Harrigan CD, Stern CD. OpenMM 7: Rapid development of high performance algorithms for molecular dynamics. PLoS Computational Biology. 2017; 13(7): e1005659.
25. Karthika C, Sureshkumar R, Zehravi M, Akter R, Ali F, Ramproshad S, Mondal B, Tagde P, Ahmed Z, Khan FS, Rahman MH, Cavalu S. Multidrug Resistance of Cancer Cells and the Vital Role of P-Glycoprotein. Life (Basel). 2022; 12(6): 897.
26. Catalano A, Iacopetta D, Ceramella J, Scumaci D, Giuzio F, Saturnino C, Aquaro S, Rosano C, Sinicropi MS. Multidrug resistance (MDR): A widespread phenomenon in pharmacological therapies. Molecules. 2022; 27(3): 616.
27. Tan BL, Norhaizan ME. Curcumin combination chemotherapy: The implication and efficacy in cancer. Molecules. 2019; 24(14): 2527.
28. Yoo HH, Lee M, Chung HJ, Lee SK, Kim DH. Effects of diosmin, a flavonoid glycoside in citrus fruits, on P-glycoprotein-mediated drug efflux in human intestinal Caco-2 cells. Journal of Agricultural and Food Chemistry. 2007; 55(18): 7620-5.
29. Bhavesh KM, Ragin S, Bhavin B, Upendra P, Dhiren D, Ghanshyam P. Biological, pharmaceutical and analytical considerations of CaCo-2 Monolayer. Research Journal of Pharmacy and Technology. 2013; 6(4): 336-344 .
30. Bansal T, Jaggi M, Khar R, Talegaonkar S. Emerging significance of flavonoids as P-glycoprotein inhibitors in cancer chemotherapy. Journal of Pharmacy and Pharmaceutical Sciences. 2009; 12(1): 46-78.
31. Andersen V, Svenningsen K, Knudsen LA, Hansen AK, Holmskov U, Stensballe A, Vogel U. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology. World Journal of Gastroenterology. 2015; 21(41): 11862.
32. Liu Z, Zhu H, Qu S, Tang L, Cao L, Yu W, Yang X, Jiang S, Zhu D, Tan C, Yu L. Pyramidatine (Z88) sensitizes vincristine-resistant human oral cancer (KB/VCR) cells to chemotherapeutic agents by inhibition of P-glycoprotein. Anti-Cancer Agents in Medicinal Chemistry. 2018; 18(2): 286-294.
33. Cort A, Ozben T. Natural product modulators to overcome multidrug resistance in cancer. Nutrition and Cancer. 2015; 67(3): 411-423.
34. Nie S, Huang Y, Shi M, Qian X, Li H, Peng C, Kong B, Zou X, Shen S. Protective role of ABCG2 against oxidative stress in colorectal cancer and its potential underlying mechanism. Oncology Reports. 2018; 40(4): 2137-2146.
35. Singh PK, Singh R, Singh S. Cinnamic acid induced changes in reactive oxygen species scavenging enzymes and protein profile in maize (Zea mays L.) plants grown under salt stress. Physiology and Molecular Biology of Plants. 2013; 19(1): 53-59.
36. Jainey PJ, Pramatha, MJ, Zakiya Fathima C, Rupal RS. Green Synthesis, Multitargeted Molecular Docking and ADMET Studies of Chalcones Based Scaffold as Anti-Breast Cancer Agents. Research Journal of Pharmacy and Technology. 2023; 16(5): 2215-2.
37. Honma M, Yamada M, Yasui M, Horibata K, Sugiyama KI, Masumura K. In vivo and in vitro mutagenicity of perillaldehyde and cinnamaldehyde. Genes and Environment. 2021; 43: 1-11.
38. Muhammad DRA, Dewettinck K. Cinnamon and its derivatives as potential ingredient in functional food—A review. International Journal of Food Properties. 2017; 20(sup2): 2237-2263.
39. Westover D, Li F. New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies. Journal of Experimental and Clinical Cancer Research. 2015; 34: 159.